| P2093 | author name string | M Heckmann | |
| P2860 | cites work | Transforming growth factor-beta2 and connective tissue growth factor in proliferative vitreoretinal diseases: possible involvement of hyalocytes and therapeutic potential of Rho kinase inhibitor | Q24338400 |
| | Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity | Q33210617 |
| | Lack of association between insulin-like growth factor I receptor G(+3174)A polymorphism and retinopathy of prematurity | Q33229821 |
| | Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins | Q33775844 |
| | Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor | Q34477473 |
| | Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization | Q34749337 |
| | HLF/HIF-2alpha is a key factor in retinopathy of prematurity in association with erythropoietin | Q34775400 |
| | Retinopathy of prematurity: clinical implications of retinal development | Q35066325 |
| | Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity | Q35108428 |
| | Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis | Q35817458 |
| | Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. | Q35897076 |
| | IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. | Q35973404 |
| | Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies | Q36172256 |
| | Anti-vascular endothelial growth factor therapy for ocular neovascular disease | Q37046559 |
| | Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy | Q37607034 |
| | Lack of association of the VEGF gene promoter (-634 G-->C and -460 C-->T) polymorphism and the risk of advanced retinopathy of prematurity | Q40267673 |
| | Genetic polymorphisms and retinopathy of prematurity. | Q40508238 |
| | Effects of marginal hypoxemia on recovery from oxygen-induced retinopathy in the kitten model. | Q41583045 |
| | Adenosine receptor antagonists and retinal neovascularization in vivo | Q43811201 |
| | Localization of VEGF receptor-2 (KDR/Flk-1) and effects of blocking it in oxygen-induced retinopathy | Q43871264 |
| | Hypoxic oxygen fluctuations produce less severe retinopathy than hyperoxic fluctuations in a rat model of retinopathy of prematurity | Q44619484 |
| | Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth | Q44640538 |
| | Norrie disease gene sequence variants in an ethnically diverse population with retinopathy of prematurity. | Q46624875 |
| | Elevated erythropoietin mRNA and protein concentrations in the developing human eye. | Q46689938 |
| | Assessment of the contribution of insulin-like growth factor I receptor 3174 G-->A polymorphism to the progression of advanced retinopathy of prematurity. | Q46873646 |
| | Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity | Q47629197 |
| | Postnatal retinal vascular development of the puppy. | Q51825536 |
| | A novel model of retinopathy of prematurity simulating preterm oxygen variability in the rat. | Q52144285 |
| | Pathological but not physiological retinal neovascularization is altered in TNF-Rp55-receptor-deficient mice. | Q54574380 |
| | Prenatal Risk Factors for Severe Retinopathy of Prematurity Among Very Preterm Infants of the Australian and New Zealand Neonatal Network | Q57391156 |
| | Genetic Polymorphisms of Vascular Endothelial Growth Factor and Angiopoietin 2 in Retinopathy of Prematurity | Q58763385 |
| | Transcutaneous oxygen levels in retinopathy of prematurity | Q71567090 |
| | Oxygen and the retinal blood vessels | Q72650980 |
| | Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor | Q73226153 |
| | Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes | Q73401253 |
| | Oxygen studies in retrolental fibroplasia. IV. Clinical and experimental observations | Q73578543 |
| | Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis | Q73640440 |
| | Experimental approach to the pathogenesis of retrolental fibroplasia. I. Changes of the eye induced by exposure of newborn mice to concentrated oxygen | Q73706796 |
| | Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials | Q74034570 |
| | Pathogenesis of retinopathy of prematurity | Q74678823 |
| | Retinopathy of prematurity | Q79858093 |
| | The incidence and course of retinopathy of prematurity: findings from the early treatment for retinopathy of prematurity study | Q81920787 |
| P433 | issue | 12 | |
| P407 | language of work or name | German | Q188 |
| P304 | page(s) | 1101-1107 | |
| P577 | publication date | 2008-12-01 | |
| P1433 | published in | Ophthalmologe | Q15759094 |
| P1476 | title | [Pathogenesis of retinopathy of prematurity]. | |
| P478 | volume | 105 | |